可转换的水凝注射顺序调节糖尿病牙周炎
Jinmin Zhou1, Houxuan Li1, Shuhong Li1
1College of Stomatology, Chongqing Key Laboratory of Oral Diseases, Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing Medical University, Chongqing 401147, China.
ACS biomaterials science & engineering
|January 10, 2025
概括
这项研究开发了一种用于糖尿病牙周炎治疗的新型水凝系统 (TOOTH). 它连续释放抗炎剂和生长因子,以减少骨质损失和促进愈合.
科学领域:
- 生物材料科学 生物材料科学
- 牙周病学 牙周病学
- 再生医学是一种再生医学.
背景情况:
- 糖尿病通过增加活性氧物种 (ROS) 加剧牙周炎,导致牙周骨损失显著.
- 有效的治疗需要同时减少炎症和膜骨再生,理想情况下是通过有序的,不干扰的治疗方法.
研究的目的:
- 开发一个连续的持续释放系统用于糖尿病牙周治疗.
- 创建一种能够减少炎症并以受控的方式促进骨再生的双重药物输送系统.
主要方法:
- 构建一个以热质伊米达酸框架-8 (ZIF-8) 修饰的奇托热敏水凝 (TOOTH).
- 顺序加载和释放化学修饰的四环素-3 (CMT-3) 用于ROS清除和血小板衍生的生生长因子-BB (PDGF-BB) 用于骨质生成.
- 通过控制 ZIF-8 颗粒大小来调节释放间隔.
主要成果:
- 在特定的微环境条件下,TOOTH系统证明了CMT-3的顺序释放,其次是PDGF-BB.
- 在体外和体内研究证实了TOOTH在治疗糖尿病牙周炎的生物相容性和有利的治疗作用.
- 控制释放有效减少炎症,促进牙周组织再生.
结论:
- 开发的TOOTH系统为糖尿病牙周炎的顺序,控制的药物输送提供了一个有希望的策略.
- 这种方法促进了炎症管理和膜骨再生,显示了临床翻译的潜力.
更多相关视频
相关概念视频
Insulin Formulations: Types and Delivery
165
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
165
Insulin: Dosing Regimen and Adverse Effects
142
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
142
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166


